top of page
Zerpidio Registered Logo.png
ABOUT ZERPIDIO

Product Information

What is Zerpidio and its Composition?

Zerpidio is known as an antineoplastic or anticancer agent that belongs to a class called monoclonal antibodies. Zerpidio contains an active ingredient serplulimab.

Serplulimab is a humanized monoclonal antibody which binds to the programmed cell death-1 (PD-1) receptor and blocks its interaction with ligands, PD-L1 and PD-L2, and it potentiates T-cell responses, including anti-tumor responses.

What is Zerpidio's Presentation?

Zerpidio available as solution for infusion in vials containing Serplulimab 100 mg/10 mL.

What does Zerpidio Look Like?

Zerpidio is formulated as a colorless to slightly yellow, clear to slightly opalescent liquid.

What is Zerpidio Used for?

Zerpidio is used in combination with carboplatin and etoposide for treatment of adult patients with a type of lung cancer called Extensive-Stage Small Cell Lung Cancer (ES-SCLC). Zerpidio is used when the ES-SCLC has not previously been treated.

Zerpidio is used in combination with carboplatin and albumin-bound paclitaxel for treatment of adult patients with locally advanced or metastatic squamous non-small cell lung cancer (squamous NSCLC), not previously been treated.

How is Zerpidio Given?

Zerpidio must be prepared by a healthcare professional (pharmacist) before treatment and will be given in a hospital by a doctor or nurse.

Zerpidio is given by intravenous infusion for about 1 hour for the first infusion and over 30 minutes for the next infusion.

How Much Zerpidio is Given?

Zerpidio recommended dose for the treatment of ES-SCLC and sqNSCLC is 4.5 mg/kg every 3 weeks or 300 mg every 3 weeks.

What Should You do if Zerpidio Treatment is Missed?

If you miss a dose of Zerpidio, call your doctor straight away to reschedule your appointment. It is very important that you do not miss a dose of this medicine.

What Things Should You Consider Before Using Zerpidio?

Tell your doctor if :

- You have a history of :

  • Allergic reaction to other monoclonal antibody therapies

  • Kidney damage

  • Autoimmune disease

  • Organ transplant

  • Lung problems or breathing problems

  • Liver problems

- You are pregnant or plan to become pregnant

- You are allergic to any other medicines or any other substances such as foods, preservatives or dyes.

Zerpidio Serplulimab 100mg

Serplulimab is the first-line anti PD-1 of choice for Extensive-Stage Small-Cell Lung Cancer

Zerpidio Profile
  • Badan POM-Approved Indications

    Serplulimab is approved by BPOM Indonesia for ES-SCLC and Sq-NSCLC

    NMPA-Approved Indications

    Serplulimab is approved by NMPA China for MSI-H solid tumors, Sq-NSCLC, ES-SCLC, and ESCC

    EMA-Approved Indications

    Serplulimab is approved by the European Medicines Agency (EMA) for ES-SCLC

    FDA-Approved as orphan drug

    Serplulimab approved by United States Food and Drug Administration (US FDA) as an orphan drug for ES-SCLC

    Thai FDA-Approved Indications

    Serplulimab is approved by Thai FDA for ES-SCLC and Sq-NSCLC

    NPRA-Approved Indications

    Serplulimab is approved by National Pharmaceutical Regulatory Agency (NPRA) for ES-SCLC

    HSA SG-Approved Indications

    Serplulimab is approved by Health Science Authority (HSA) for ES-SCLC

  • Tell your doctor if:

    • You have a history of :

      • Allergic reaction to other monoclonal antibody therapies

      • Kidney damage

      • Autoimmune disease

      • Organ transplant

      • Lung problems or breathing problems

      • Liver problems

    • You are pregnant or plan to become pregnant

    • You are allergic to any other medicines or any other substances such as foods, preservatives or dyes.


    Tell your doctor or nurse immediately if you have any signs or symptoms below:

    • Inflammation of the lungs: new or worsening cough, shortness of breath, or chest pain;

    • Inflammation of the liver: nausea or vomiting, feeling less hungry, pain on the right side of your stomach, yellowing of skin or whites of eyes, drowsiness, dark urine or bleeding or bruising more easily than normal;

    • Inflammation of the intestines: diarrhoea or more bowel movements than usual, or stools that are black, tarry or sticky with blood or mucus, severe stomach pain or tenderness;

    • Inflammation of glands (especially the thyroid, adrenal, pituitary and pancreas): fast heart rate, extreme tiredness, weight gain or weight loss, dizziness or fainting, hair loss, feeling cold, constipation, headaches that will not go away or unusual headaches, abdominal pain, nausea and vomiting;

    • Type 1 diabetes: high blood sugar, feeling more hungry or thirsty than usual, passing urine more often than usual, fast and deep breathing, confusion, or a sweet smell to your breath, a sweet or metallic taste in your mouth or a different odour to your urine or sweat;

    • Inflammation of the kidneys: decrease in the amount of urine you pass;

    • Inflammation of the skin: rash, itching, skin blistering, or ulcers in the mouth or on another moist surfaces;

    • Inflammation of the heart muscle: chest pain, shortness of breath, or irregular heartbeat;

    • Inflammation of the eyes;

    • Inflammation or problem of the muscles: muscle pain, or weakness, or rapid fatigue of the muscles;

    • Infusion-related reactions: chills or shaking, itching or rash, flushing, shortness of breath or wheezing, dizziness or fever ;

    • Inflammation of the brain (encephalitis) or inflammation of the membrane around the spinal cord and brain (meningitis): seizure, neck stiffness, headache, fever, chills, vomiting, eye sensitivity to light, confusion and sleepiness;

    • Inflammation of the nerves: pain, weakness, and paralysis in the extremities (Guillain-Barre syndrome)

    • Low number of platelets: bleeding (nose or gum bleeding) and/or bruising.

    Zerpidio should not be used in children and adolescents under 18 years of age. The safety and efficacy of Zerpidio in children and adolescents below 18 years of age have not been established. No data are available.


    The use of Zerpidio during pregnancy and breast-feeding is not recommended. If you think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.


    The most frequent adverse events of Zerpidio in combination with carboplatin and etoposide for treatment in adults with extensive-stage small cell lung cancer include neutropenia, leukopenia, and anemia.


    ​The most frequent adverse events of Zerpidio in combination with carboplatin and nanoparticle albumin bound paclitaxel for treatment in adult patients with advanced squamous non-small cell lung cancer (metastasis/locally advanced) include anaemia, neutrophil count decreased, and white blood cell count decreased.

    These are not all the possible side effects of Zerpidio. Talk to your health care provider for medical advice about side effects.


    ​Please read the accompanying Medication Guide for Zerpidio and discuss it with your doctor. The physician Prescribing Information also is available.


    Important Safety Information


  • Badan POM-Approved Indications

    Serplulimab is approved by BPOM Indonesia for ES-SCLC and Sq-NSCLC

    NMPA-Approved Indications

    Serplulimab is approved by NMPA China for MSI-H solid tumors, Sq-NSCLC, ES-SCLC, and ESCC

    EMA-Approved Indications

    Serplulimab is approved by the European Medicines Agency (EMA) for ES-SCLC

    FDA-Approved as orphan drug

    Serplulimab approved by United States Food and Drug Administration (US FDA) as an orphan drug for ES-SCLC

    Thai FDA-Approved Indications

    Serplulimab is approved by Thai FDA for ES-SCLC and Sq-NSCLC

    NPRA-Approved Indications

    Serplulimab is approved by National Pharmaceutical Regulatory Agency (NPRA) for ES-SCLC

    HSA SG-Approved Indications

    Serplulimab is approved by Health Science Authority (HSA) for ES-SCLC


  • Important Safety Information


    Tell your doctor if:

    • You have a history of :

      • Allergic reaction to other monoclonal antibody therapies

      • Kidney damage

      • Autoimmune disease

      • Organ transplant

      • Lung problems or breathing problems

      • Liver problems

    • You are pregnant or plan to become pregnant

    • You are allergic to any other medicines or any other substances such as foods, preservatives or dyes.


    Tell your doctor or nurse immediately if you have any signs or symptoms below:

    • Inflammation of the lungs: new or worsening cough, shortness of breath, or chest pain;

    • Inflammation of the liver: nausea or vomiting, feeling less hungry, pain on the right side of your stomach, yellowing of skin or whites of eyes, drowsiness, dark urine or bleeding or bruising more easily than normal;

    • Inflammation of the intestines: diarrhoea or more bowel movements than usual, or stools that are black, tarry or sticky with blood or mucus, severe stomach pain or tenderness;

    • Inflammation of glands (especially the thyroid, adrenal, pituitary and pancreas): fast heart rate, extreme tiredness, weight gain or weight loss, dizziness or fainting, hair loss, feeling cold, constipation, headaches that will not go away or unusual headaches, abdominal pain, nausea and vomiting;

    • Type 1 diabetes: high blood sugar, feeling more hungry or thirsty than usual, passing urine more often than usual, fast and deep breathing, confusion, or a sweet smell to your breath, a sweet or metallic taste in your mouth or a different odour to your urine or sweat;

    • Inflammation of the kidneys: decrease in the amount of urine you pass;

    • Inflammation of the skin: rash, itching, skin blistering, or ulcers in the mouth or on another moist surfaces;

    • Inflammation of the heart muscle: chest pain, shortness of breath, or irregular heartbeat;

    • Inflammation of the eyes;

    • Inflammation or problem of the muscles: muscle pain, or weakness, or rapid fatigue of the muscles;

    • Infusion-related reactions: chills or shaking, itching or rash, flushing, shortness of breath or wheezing, dizziness or fever ;

    • Inflammation of the brain (encephalitis) or inflammation of the membrane around the spinal cord and brain (meningitis): seizure, neck stiffness, headache, fever, chills, vomiting, eye sensitivity to light, confusion and sleepiness;

    • Inflammation of the nerves: pain, weakness, and paralysis in the extremities (Guillain-Barre syndrome)

    • Low number of platelets: bleeding (nose or gum bleeding) and/or bruising.

    Zerpidio should not be used in children and adolescents under 18 years of age. The safety and efficacy of Zerpidio in children and adolescents below 18 years of age have not been established. No data are available.


    The use of Zerpidio during pregnancy and breast-feeding is not recommended. If you think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.


    The most frequent adverse events of Zerpidio in combination with carboplatin and etoposide for treatment in adults with extensive-stage small cell lung cancer include neutropenia, leukopenia, and anemia.


    ​The most frequent adverse events of Zerpidio in combination with carboplatin and nanoparticle albumin bound paclitaxel for treatment in adult patients with advanced squamous non-small cell lung cancer (metastasis/locally advanced) include anaemia, neutrophil count decreased, and white blood cell count decreased.

    These are not all the possible side effects of Zerpidio. Talk to your health care provider for medical advice about side effects.


    ​Please read the accompanying Medication Guide for Zerpidio and discuss it with your doctor. The physician Prescribing Information also is available.

bottom of page